Small RNA- and DNA-based gene therapy for the treatment of liver cirrhosis, where we are?
Chronic liver diseases with different aetiologies rely on the chronic activation of liver injuries which result in a fibrogenesis progression to the end stage of cirrhosis and liver failure. Based on the underlying cellular and molecular mechanisms of a liver fibrosis, there has been proposed several kinds of approaches for the treatment of liver fibrosis. Recently, liver gene therapy has been developed as an alternative way to liver transplantation, which is the only effective therapy for chronic liver diseases. The activation of hepatic stellate cells, a subsequent release of inflammatory cytokines and an accumulation of extracellular matrix during the liver fibrogenesis are the major obstacles to the treatment of liver fibrosis. Several targeted strategies have been developed, such as antisense oligodeoxynucleotides, RNA interference and decoy oligodeoxynucleotides to overcome this barriers. With this report an overview will be provided of targeted strategies for the treatment of liver cirrhosis, and particularly, of the targeted gene therapy using short RNA and DNA segments.
['Kim|Kyung-Hyun|KH|', 'Park|Kwan-Kyu|KK|']
D000818:Animals D005786:Gene Expression Regulation D015316:Genetic Therapy D006801:Humans D008103:Liver Cirrhosis D035683:MicroRNAs D016376:Oligonucleotides, Antisense D034622:RNA Interference D034741:RNA, Small Interfering D016896:Treatment Outcome
Gene therapy Liver cirrhosis Antisense Oligodeoxynucleotides Decoy Micro RNA Small interfering RNA